Table 2.
The relationship between PFS and clinical-pathological features.
| Clinical factors | HR | 95% CI | P value |
|---|---|---|---|
| Age ≤65 vs >65 |
1.34 | 0.73–2.46 | .331 |
| Progesterone receptor expression Positive vs negative |
1.03 | 0.36–2.94 | .955 |
| Human epidermal growth factor receptor 2 HER2 0 vs HER2 low |
1.09 | 0.82–1.44 | .554 |
| Menopause status Premenopausal vs postmenopausal |
0.93 | 0.68–1.27 | .668 |
| Disease status De novo metastatic vs recurrent disease |
1.90 | 1.09–3.30 | .022 |
| Visceral metastases Presence vs absence |
1.43 | 0.84–2.43 | .184 |
| Bone metastases Presence vs absence |
0.87 | 0.62–1.24 | .462 |
| Treatment agent Palbociclib vs ribociclib |
1.06 | 0.81–1.39 | .652 |
| Endocrine therapy Aromatase inhibitors vs fulvestrant |
0.49 | 0.27–0.88 | .017 |
The bold values indicate statistically significant data.